Monitor Your Skin Cancer
The Signatera™ Residual Disease Test is a custom-built blood test for people who have been diagnosed with skin cancers like melanoma or Merkel cell carcinoma. Signatera™ can detect molecular residual disease (MRD) in the form of circulating tumor DNA—small fragments of DNA released by cancer cells.
![signatera-how-it-works-1](https://www.natera.com/wp-content/uploads/2022/08/signatera-how-it-works-1-1.png)
The first time your doctor orders Signatera™, a one-time tissue sample and a blood sample are needed to build your unique test.
![signatera-how-it-works-2](https://www.natera.com/wp-content/uploads/2022/08/signatera-how-it-works-2-1.png)
After your test is built, you only need to provide a blood sample each time your doctor orders Signatera™.
![signatera-how-it-works-3](https://www.natera.com/wp-content/uploads/2022/08/signatera-how-it-works-3-1.png)
Repeated Signatera™ testing can show changes in your ctDNA levels, helping your doctor understand if your cancer is shrinking, growing, coming back, or responding to immunotherapy.
![stay-informed-skin-cancer-patient](https://www.natera.com/wp-content/uploads/2022/08/stay-informed-skin-cancer-patient.png)
Stay Informed About Your Skin Cancer
Get earlier, more precise information to help guide care
If you or a loved one have been diagnosed with skin cancer, you may be seeking answers. Signatera™ can help your doctor answer important questions such as:
- Are you responding to treatment?1
- Are there signs that the cancer has returned?2
Reduce the Unknown
Jeffrey was diagnosed with metastatic melanoma after he discovered a growth under his arm. His oncologist used Signatera™ to understand if his immunotherapy was working.
Watch Jeffrey’s story to learn how Signatera™ helped him look forward to the future again.
Inform Critical Decisions Across Your Skin Cancer Care
![1-after-surgery](https://www.natera.com/wp-content/uploads/2022/08/1-after-surgery.png)
After Surgery
Signatera™ can identify whether there are small traces of cancer remaining after surgery. This can help your doctor decide if additional treatment may be helpful.2
![2-during-treatment](https://www.natera.com/wp-content/uploads/2022/08/2-during-treatment.png)
During Treatment
Signatera™ can help determine whether you are responding to immunotherapy by assessing changes in levels of ctDNA throughout your treatment.1
![3-after-treatment](https://www.natera.com/wp-content/uploads/2022/08/3-after-treatment.png)
After Treatment
Signatera™ can help detect if your cancer is returning, possibly earlier than traditional imaging tests like CT scans.2
Common Testing Questions
Access
- Signatera™ is covered by Medicare for immunotherapy response monitoring in skin cancers and other solid tumors.
- We welcome all insurance plans. Please refer to our list of in-network plans that we participate with, or call your insurance provider.
- We offer financial assistance programs for eligible people.
More Information
- Find answers to your questions about eligibility, results, ordering, and more
- Don’t see your question? Contact us here.
Learn More
Is Signatera™ right for you?
References
1Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873-881. https://doi.org/10.1038/s43018-020-0096-5
2Akaike T, et al. Circulating tumor DNA correlates with Merkel cell carcinoma tumor burden and helps early detection of recurrence. ASCO, Chicago, Illinois, June 3-7, 2022.